What does “acetate” actually mean in sermorelin acetate?
Sermorelin is a peptide—a short chain of 29 amino acids that mirrors the first 29 residues of human growth hormone releasing hormone (GHRH). In its pure form, the peptide carries a positive charge at physiological pH. To make it stable, soluble, and suitable for injection, pharmaceutical manufacturers and compounding pharmacies pair it with an acetate counterion (CH₃COO−).
The result is sermorelin acetate: a salt form that is more chemically stable in aqueous solution and easier to formulate accurately at the doses used in clinical protocols. The acetate portion is pharmacologically inert—it does not cross the blood-brain barrier, does not bind to any receptor, and is not what drives the biological effect. What matters biologically is the sermorelin peptide itself.
This pattern is common across peptide and drug pharmaceuticals. You will find the same logic in “testosterone cypionate” (the ester determines depot release), “semaglutide sodium,” and many injectable medications. The salt form is a stability and delivery vehicle, not a distinct molecule.
What does sermorelin acetate do in the body?
Sermorelin acetate binds to GHRH receptors on the anterior pituitary gland. Activation of those receptors triggers the pulsatile release of growth hormone (GH) into systemic circulation. This is the core mechanism—and it is fundamentally different from injecting exogenous growth hormone directly.
When you inject sermorelin, you are stimulating your own pituitary to produce and release GH. The pituitary then responds to negative feedback: as IGF-1 (a downstream product of GH signaling in the liver) rises, the hypothalamus releases somatostatin, which dampens further GH release. The feedback loop remains intact.
This is why clinicians who prescribe sermorelin often prefer it over exogenous GH for most adults: the body’s regulatory mechanisms continue to operate rather than being overridden. You are supporting a natural rhythm, not replacing it.
The acetate is just a stability and delivery vehicle — pharmacologically inert — so what acts on your pituitary is the very same sermorelin peptide either way.
Why does the regulatory history of sermorelin matter?
Sermorelin acetate had an FDA-approved drug product—Geref, manufactured by Serono—which was voluntarily withdrawn from the market in 2008. The FDA withdrawal did not declare sermorelin unsafe. It was a commercial decision by the manufacturer. The molecule itself was never banned or found to present unacceptable risk.
Because the brand product is no longer available, sermorelin acetate is now exclusively available through 503A compounding pharmacies. Clinicians can prescribe it, licensed pharmacies can compound it, and patients can receive it. It is not an OTC supplement and it is not available without a prescription.
This matters practically: when you see sermorelin acetate on a prescription, it means a licensed US 503A compounding pharmacy is preparing it to your specific dose. It is not a generic version of a current brand drug. It is a compounded preparation of a molecule that has been legally prescribed and compounded for over two decades.
How does sermorelin acetate fit into growth hormone optimization?
Growth hormone secretion peaks in the early twenties and declines progressively with age—a process called somatopause. By mid-adulthood, pulsatile GH release is substantially lower than in younger years, and the downstream effects include changes in body composition (more fat, less lean mass), reduced energy, slower recovery, and disrupted sleep architecture.
Sermorelin acetate targets this mechanism directly. Rather than supplying exogenous GH (which bypasses the pituitary entirely), it works upstream: stimulating the pituitary to restore a more youthful pattern of pulsatile GH release. Research from the 1990s, including the Chapman et al. study in the Journal of Clinical Endocrinology & Metabolism, documented the GH-stimulating effect of GHRH receptor agonists in older adults.
A clinician evaluating a patient for sermorelin will typically look at IGF-1 levels as a surrogate marker of GH output—not because IGF-1 is the target, but because it is the most practical way to assess whether GH secretion is in a range consistent with the patient’s age and goals, and to monitor the protocol’s effect over time.
Why is sermorelin acetate injected rather than taken orally?
Sermorelin acetate is administered via subcutaneous injection. Peptides administered orally are degraded by digestive enzymes before they reach systemic circulation—the 29-amino-acidstructure of sermorelin would not survive the gastrointestinal tract intact. Any product marketed as “oral sermorelin” is not delivering sermorelin to the pituitary.
Subcutaneous injection delivers sermorelin into the tissue just below the skin, where it absorbs into circulation and reaches the pituitary via the bloodstream. Injection timing is relevant: GH is normally released in pulses during deep sleep, so evening administration is a common protocol choice, though clinicians vary their recommendations based on individual circumstances.
What sermorelin acetate is not
Sermorelin acetate is not human growth hormone (HGH). It does not directly introduce GH into the body. It is not anabolic in the way exogenous GH or anabolic steroids are. It is not approved to treat any disease, and PepScribe does not represent it as such.
What it is: a well-characterized GHRH analog with decades of research behind it, legally available through licensed US 503A compounding pharmacies, requiring a clinician prescription, and used in supervised protocols for adults whose GH secretion profile suggests they may benefit from pituitary stimulation.
Sermorelin vs. sermorelin acetate: side-by-side comparison
| Property | Sermorelin | Sermorelin Acetate |
|---|---|---|
| Active molecule | 29-amino-acid GHRH analog | Same 29-amino-acid GHRH analog |
| Difference | Pure peptide (conceptual/base form) | Salt form with inert acetate counterion for stability |
| Mechanism of action | Binds GHRH receptors; stimulates pituitary GH release | Identical — acetate is pharmacologically inert |
| Compounding form | Not used in practice | Standard form used by licensed US 503A pharmacies |
| FDA status | Not a separate regulatory category | Compounded; not an FDA-approved drug (Geref withdrawn 2008) |
| Requires prescription? | Yes | Yes |
Frequently asked questions
What is sermorelin acetate?
Sermorelin acetate is the acetate salt form of sermorelin — a synthetic peptide that mimics the first 29 amino acids of human growth hormone releasing hormone (GHRH). The acetate salt is the standard compounding form: it improves stability in solution and is what licensed 503A compounding pharmacies use when preparing sermorelin for injection.
Is sermorelin acetate different from sermorelin?
No in terms of biological activity. The active molecule is sermorelin in both cases. "Sermorelin acetate" names the pharmaceutical salt used in compounded preparations. The acetate counterion is inert pharmacologically — it does not change how sermorelin acts on the pituitary.
How does sermorelin work?
Sermorelin binds to GHRH receptors on the anterior pituitary gland and stimulates the pulsatile release of growth hormone (GH). Because it works through your own pituitary rather than directly injecting GH, the body's natural feedback mechanisms (IGF-1 acting on the hypothalamus) remain intact, which is one reason clinicians prefer it over exogenous GH for most wellness protocols.
Who is a candidate for sermorelin?
Adults with signs of declining growth hormone secretion — typically fatigue, changes in body composition, reduced recovery, and sleep disruption — who have been cleared through clinician evaluation are common candidates. A licensed clinician reviews health history and, where appropriate, lab values (IGF-1, GH stimulation) before prescribing.
Is sermorelin FDA-approved?
Sermorelin acetate had an FDA-approved brand product (Geref) that was voluntarily withdrawn from the market by the manufacturer. The molecule remains legally available through licensed US 503A compounding pharmacies as a compounded medication. Compounded sermorelin is not an FDA-approved drug and should not be represented as such.
What are common side effects of sermorelin?
The most commonly reported effects are injection-site reactions (redness, swelling) and transient flushing. Because sermorelin stimulates pulsatile GH release rather than flooding the system with exogenous GH, the side-effect profile is generally milder than exogenous growth hormone. A clinician evaluation establishes whether sermorelin is appropriate for your history.